文献速递儿童内分泌与遗传代谢儿童呼吸

加拿大儿童症状性肾上腺抑制的监测研究

Symptomatic adrenal suppression among children in Canada.
PubMed 文献 · Arch Dis Child · 2016-11-09

最常见表现为生长障碍(35%)和非特异性症状(28%),13%发生肾上腺危象,80%曾使用吸入性糖皮质激素。

要点

  • 症状性肾上腺抑制在儿童中可表现为生长障碍或非特异性症状,需警惕。
  • 80%病例与吸入性糖皮质激素相关,即使常用剂量也可能导致肾上腺抑制。
  • 13%的病例发生肾上腺危象,提示需密切监测并避免应激诱发危象。

核心结论

  • 症状性肾上腺抑制在儿童中导致显著疾病负担,包括肾上腺危象风险。
  • 报告的最低发病率基于全体儿科人群,在暴露于糖皮质激素的儿童中会更高。

研究设计与样本

  • 通过加拿大儿科监测计划,每月调查2500余名儿科医生,为期2年(2010年4月至2012年3月),报告新发症状性肾上腺抑制病例。

主要发现

  • 最常见表现为生长障碍(35%)、非特异性症状(28%)或两者兼有(13%)。
  • 6例(13%)发生肾上腺危象。
  • 许多儿童使用了高剂量但常用的吸入性糖皮质激素处方剂量。

临床怎么用

  • 对所有使用糖皮质激素(包括吸入性)的儿童,应密切监测生长和可能的肾上腺抑制症状,症状可能非特异性。
  • 医生应认识到肾上腺抑制风险,频繁重新评估糖皮质激素剂量,并使用最低有效剂量。

局限性

  • 报告的最低发病率基于全体儿科人群,可能低估了暴露于糖皮质激素儿童中的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adrenal suppression (AS) is an under-recognised side effect of glucocorticoid (GC) use. AS may go undetected until a physiological stress precipitates an adrenal crisis. The incidence of AS has not been established. We sought to estimate the minimum national incidence and presenting features of paediatric symptomatic AS. METHODS: Through the established methodology of the Canadian Paediatric Surveillance Program, over 2500 paediatricians were surveyed monthly for 2 years (April 2010-March 2012) to report new cases of symptomatic AS. RESULTS: Forty-six cases of symptomatic AS were confirmed. The estimated annual incidence is 0.35/100 000 children aged 0-18 years (95% CI 0.26 to 0.47). The most common presentations were growth failure (35%), non-specific symptoms (28%) or both (13%). Adrenal crisis occurred in six cases (13%). Thirty-seven children (80%) had received inhaled corticosteroid (ICS) alone or in combination with other GC forms. Many children received high but commonly prescribed doses of ICS. CONCLUSIONS: AS is responsible for significant morbidity in children, including susceptibility to adrenal crisis. The minimal estimated incidence reported is for the entire paediatric population and would be much higher in the at-risk group (ie, children treated with GCs). Close monitoring of growth and possible symptoms of AS, which may be non-specific, are important in children on all forms of GC therapy including ICS. To reduce the risk of AS, physicians must be aware of the risk of AS, revisit GC doses frequently and use the lowest effective dose.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Goldbloom EB, Mokashi A, Cummings EA, et al. Symptomatic adrenal suppression among children in Canada. Arch Dis Child. 2016. PMID: 28320817. doi:10.1136/archdischild-2016-311223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。